Chemotherapy for elderly patients with advanced colorectal carcinoma

References

• Benson AB, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologist reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J. Clin. Oncol.9, 2067–2075 (1991).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ et al. Under-representation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med.241, 2061–2066 (1999).
   Google Scholar
• Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br. Med. J.32, 351–355 (2000).
   Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355, 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• DeGramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18, 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22, 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of he Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol.23, 4866–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Balducci L. Evidence-based management of cancer in the elderly. Cancer Control7, 368–376 (2000).
   PubMedGoogle Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist5, 224–237 (2000).
   PubMedGoogle Scholar
• Balducci L, Ershler WB. Cancer and ageing: a nexus at several levels. Nat. Rev. Cancer5, 655–662 (2005).
   PubMed Web of Science ®Google Scholar
• Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat. Rev.31, 380–402 (2005).
   PubMed Web of Science ®Google Scholar
• Stuck AE, Siu AL, Wieland GD et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet342, 1032–1036 (1993).
   PubMed Web of Science ®Google Scholar
• Extermann M, Meyer J, McGinnis M et al. A comprehensive geriatric intervention detect multiple problems in older breast cancer patients. Crit. Rev. Oncol. Hematol.49, 69–75 (2004).
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J. Gerontol.56, 146–156 (2001).
   Google Scholar
• Lachs MS, Feinstein AR, Coonley LM et al. A simple procedure for general screening for functional disanility in elderly patients. Ann. Intern.112, 699–706 (1990).
   PubMed Web of Science ®Google Scholar
• Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument. Am. J. Med.100, 438–443 (1996).
   PubMed Web of Science ®Google Scholar
• Moore AA, Siu AL, Partridge BA et al. A randomized trial of office-based screening for common problems in older persons. Am. J. Med.102, 371–378 (1997).
   PubMedGoogle Scholar
• Povoski SP, Fong Y, Sgouros SC et al. Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann. Surg. Oncol.5, 9–15 (1998).
   PubMed Web of Science ®Google Scholar
• Fong Y, Saldinger PF, Akhurst T et al. Utility of F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am. J. Surg.178, 282–287 (1999).
   PubMed Web of Science ®Google Scholar
• Strasberg SM, Dehdashti F, Siegel BA et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann. Surg.233, 293–299 (2001).
   PubMed Web of Science ®Google Scholar
• Arhurst T, Kates TJ, Mazumdar M et al. Recent chemotherapy reduces the sensitivity of fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J. Clin. Oncol.23, 8713–8716 (2005).
   PubMedGoogle Scholar
• Van Der Molen B. Relating information needs to the cancer experience. Eur. J. Cancer8, 238–244 (1999).
   Google Scholar
• Ainslie N, Beisecker AE. Changes in decisions by elderly persons based on treatment description. Arch. Intern. Med.154, 2225–2233 (1994).
   PubMedGoogle Scholar
• Ajaj A, Singh MP, Abdulla AJ. Should elderly patients be told they have cancer? Br. Med. J.323, 1160 (2001).
   PubMedGoogle Scholar
• Kahana E, Kahana B. Patient pro-activity enhancing doctor–patient–family communication in cancer prevention and care among the aged. Patient Educ. Couns.50, 67–73 (2003).
   PubMed Web of Science ®Google Scholar
• Greene MG, Adelman RD, Majerovtiz SD. Physician and older patient support in the medical encounter. Health Commun.8, 263–279 (1996).
   Web of Science ®Google Scholar
• Greene M, Majerovitz D, Adelman R, Rizzo C. The effects of the presence of a third person on the physician–older patient medical interview. J. Am. Geriatr. Soc.42, 413–419 (1994).
   PubMed Web of Science ®Google Scholar
• Greene MG, Hoffman S, Charon R, Adelman R. Psychosocial concerns in the medical encounter: a comparison of the interactions of doctors with their old and young patients. Gerontologist27, 164–168 (1987).
   PubMed Web of Science ®Google Scholar
• Kutner JS, Vu KO, Prindiville SA, Byers TE. Patient age and cancer treatment decisions. Patient and physician views. Cancer Pract.8, 114–119 (2000).
   PubMedGoogle Scholar
• Velikova G, Stark D, Selby P. Quality of life instruments in oncology. Eur. J. Cancer35, 1571–1580 (1999).
   PubMedGoogle Scholar
• Bennabum D, Forman W, Vellas B, Albarete J. Life expectancy, comorbidity, and quality of life. Clin. Geriatr. Med.13, 33–53 (1997).
   PubMedGoogle Scholar
• Dancey J, Zee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual. Life Res.6, 151–158 (1997).
   PubMed Web of Science ®Google Scholar
• Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology. Eur. J. Cancer34, 1181–1186 (1998).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Olafsdottir M, Palman L, Sjoeden P, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. Eur. J. Cancer Clin. Oncol.25, 829–835 (1989).
   PubMedGoogle Scholar
• Sprangers MA, te Velde A, Aaronson NK et al. The construction and testing of the EORTC colorrectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur. J. Cancer35, 238–247 (1999).
   PubMed Web of Science ®Google Scholar
• Ward WL, Hahn EA, Mo F et al. Reliability and validity of the functional assessment of cancer therapy-colorrectal (FACT-C) QOL instrument. Qual. Life Res.8, 181–195 (1999).
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med. Care30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Ware Jr J, Kosinsky M, Keller SD. A 12-item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med. Care34, 220–223 (1996).
   PubMed Web of Science ®Google Scholar
• Thomé B, Dykes AK, Hallberg IR. Quality of life in old people with and without cancer. Qual. Life Res.13, 1067–1080 (2004).
   PubMedGoogle Scholar
• Thomé B, Hallberg IR. Quality of life in older people with cancer-a gender perspective. Eur. J. Cancer Care13, 454–463 (2004).
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann. Surg.230, 663–669 (1999).
   PubMedGoogle Scholar
• Nagano Y, Nojiri K, Matsuo K et al. The impact of advanced age on hepatic resection of colorectal liver metastases. J. Am. Coll. Surg.201, 511–516 (2005).
   PubMedGoogle Scholar
• Yan TD, Padang R, Morris DL. Long-term results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: long term survival can be achieved with multiple liver metastases. J. Am. Coll. Surg.202, 100–111 (2006).
   PubMed Web of Science ®Google Scholar
• Rhim H, Dodd GD. Radiofrequency thermal ablation of liver tumors. J. Clin. Ultrasound27, 221–229 (1999).
   PubMed Web of Science ®Google Scholar
• Berber E, Siperstein AE. Predictors of survival after radiofrequency termal ablation of colorectal cancer metastases to the liver. J. Clin. Oncol.23, 1358–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Curley SA, Izzo F, Delrio P et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann. Surg.230, 1–8 (1999).
   PubMed Web of Science ®Google Scholar
• Wood TF, Rose DM, Chung M et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann. Surg. Oncol.7, 593–600 (2000).
   PubMed Web of Science ®Google Scholar
• Solbiati L, Livraghi T, Goldberg SN et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer. Long-term results in 117 patients. Radiology221, 159–166 (2001).
   PubMed Web of Science ®Google Scholar
• Baducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol. Oncol. Clin. N. Am.14, 235–250 (2000).
   PubMedGoogle Scholar
• Chen H, Cantor A, Meyer J et al. Can older cancer tolerate chemotherapy? A prospective pilot study. Cancer97, 1107–1114 (2003).
   PubMedGoogle Scholar
• Monfardini S, Sorio R, Boes GH et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new drug development studies. Cancer76, 333–338 (1995).
   PubMedGoogle Scholar
• Stein BN, Petrelli NJ, Douglass HO et al. Age and sex are independent predictors of 5-FU toxicity. Analysis of large scale Phase III trial. Cancer75, 11–17 (1995).
   PubMed Web of Science ®Google Scholar
• Chiara S, Nobile MT, Vicenti M et al. Advanced colorectal cancer in the ederly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother. Pharmacol.42, 336–340 (1998).
   PubMed Web of Science ®Google Scholar
• Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol.17, 2412–2418 (1999).
   PubMed Web of Science ®Google Scholar
• Folprecht G, Cunningham D, Ross P et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol.15, 1330–1338 (2004).
   PubMedGoogle Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol.19, 4097–4106 (2001).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19, 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20, 3617–3627 (2002).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20, 3605–3616 (2002).
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Ficht I et al. Patients preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol.15, 110–115 (1997).
   PubMed Web of Science ®Google Scholar
• Feliu J, Gonzalez Baron M, Espinosa E et al. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer79, 1884–1889 (1997).
   PubMedGoogle Scholar
• Feliu J, Mel JR, Camps C et al. Raltitrexet in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur. J. Cancer38, 1204–1211 (2002).
   PubMedGoogle Scholar
• Feliu J, Escudero P, Llosa F et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J. Clin. Oncol.23, 3104–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Beretta G, Bollina R, Labianca R et al. A controlled trial of supportive care (SC) versus supportive care plus 5-fluorouracil/folinic acid for advanced metastatic gastrointestinal carcinomas in elderly. Proceedings of the American Society of Clinical Oncology, TX, USA, 13, 221 (1994).
   Google Scholar
• Saltz LB, Cox JV, Blanke LS et al. Irinotecan plus fluorouracil and leucovorin for metastatic 5FU colorectal cancer. N. Engl. J. Med.343, 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol.23, 4856–4865 (2005).
   PubMed Web of Science ®Google Scholar
• Bollina R, Beretta G, Toniolo D et al. Capiri: a good combination regimen in first line elderly CRC patients. Proceedings of the American Society of Clinical Oncology, IL, USA, 31 May–3 June, 332s, (2003).
   Google Scholar
• Sastre J, Marcuello E, Massutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group or the Treatment of Digestive Tumors Study. J. Clin. Oncol.23, 3545–3551 (2005).
   PubMed Web of Science ®Google Scholar
• Buzzi F, Natale D, Farris A et al. Capecitabine (XEL) plus oxaliplatin (OX) tailored regimen for the first-line treatment of elderly patients (pts) with metastatic colorectal cancer (MCC). Final results of the Southern Italy Cooperative Oncology Group (SIGOG) trial 0108. Proceedings of the American Society of Clinical Oncology, FL, USA, 13–17 May, 266s (2005).
   Google Scholar
• Salud A, Escudero P, Feliu J et al. XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). Proceedings of the American Society of Clinical Oncology, FL, USA, 13–17 May, 276s (2005).
   Google Scholar
• Hurwith H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMedGoogle Scholar
• Cunningham D, Humblet Y, Siena S et al. A randomised comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Malik I, Hecht R, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology, FL, USA, 13–17 May, 251 (2005).
   Google Scholar